Ovid Therapeutics Inc (OVID) — Who's Buying and Selling (13F, Q2 2026)

OVID ranks #3972 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

133 institutions disclose a position in OVID, but none treat it as a major bet — even Propel Bio Management, LLC, its most concentrated holder, allocates just 1.6% of its own portfolio to it.

Assenagon Asset Management S.A. has trimmed its OVID position for two straight quarters, cutting it by $461.9K while still holding $43.7K.

OVID is down 4.9% today, but institutions show net buying of $100.5M this quarter — a divergence between today's price move and the underlying institutional flow.

OVID reported a net loss of $34.5M over the trailing twelve months.

• Not yet profitable — net loss of $34.5M over the trailing twelve months
• Revenue declined 76.2% year over year
• Net income improved year over year, from -$38.2M to -$34.5M
• Operating cash flow was negative, using $38.3M in cash
• Current ratio of 8.97x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.16x equity — within a conventional range